Anocca is a Swedish biotechnology company pioneering next-generation T-cell receptor-engineered T-cell (TCR-T) therapies to treat solid tumors. Founded in 2014 by CEO Reagan Jarvis, Anocca originated from Jarvis's vision as a researcher to decode T-cell immunity. He pitched this concept to a leading Swedish industrialist, who became the company's co-founder and initial financier.

Headquartered in Södertälje, Anocca has developed a proprietary platform that combines advanced cell biology, gene editing, and custom software to systematically analyze T-cell biology at scale. This platform enables the identification and engineering of T-cell receptors (TCRs) to create personalized immunotherapies targeting hard-to-treat cancers.